US pharmaceuticals giant Johnson & Johnson on Thursday announced it was buying Swiss medical firm Actelion for $30 billion (27.9 billion euros).

Johnson & Johnson's CEO and chairman Alex Gorsky said in a statement that the acquisition of Actelion, a leader in medicines treating high blood pressure, offered "compelling value" to shareholders in both companies.